Publish in this journal
Journal Information
Vol. 53. Num. 12.December 2017
Pages 659-704
Vol. 53. Num. 12.December 2017
Pages 659-704
Scientific Letter
DOI: 10.1016/j.arbr.2017.10.007
Mycobacterium xenopi and Squamous Cell Carcinoma of the Lung
Mycobacterium xenopi y carcinoma pulmonar de células escamosas
Miguel Martín Asenjoa,
Corresponding author

Corresponding author.
, Javier Miguel Martín Guerraa, María Rosa López Pedreirab, José María Prieto de Paulaa
a Servicio de Medicina Interna, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
b Servicio de Radiodiagnóstico, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
This item has received
Article information
Full Text
Download PDF
Dear Editor,
Full Text

Non-tuberculous mycobacteria (NTM) or atypical mycobacteria are aerobic bacteria of the genus Mycobacterium, the pathogenic potential of which has been known since the 1950s.1 The AIDS pandemic, the progressive increase in immunosuppressive states, and the improvement of microbiological techniques have made isolation of these microorganisms more common nowadays.2

Mycobacterium xenopi (M. xenopi) is a NTM associated with water systems that is found primarily in North America, the south east of Great Britain, and the north of France,3 and was first isolated in immunosuppressed patients. The main risk factors for the disease are chronic lung diseases, during which the organism can colonize the respiratory tract.4 Cases of mycobacterial infection have been published in cancer patients,5 but cases involving M. xenopi are exceptional. No references to the subject were found in articles retrieved from a literature for articles published in Spanish using the standard search engines, Medline and Pubmed (key words: Mycobacterium xenopi and lung cancer). We report a case of M. xenopi infection in a patient with severe COPD and a diagnosis of squamous cell carcinoma.

This was a 73-year-old man, active smoker, diagnosed with severe COPD in 2006. He consulted for asthenia, epigastric pain, weight loss, and productive cough without fever. The only relevant finding on physical examination was poor nutritional status. Clinical laboratory test results showed normochromic normocytic anemia (hemoglobin 10.8g/dl), with ESR 46mm and ferritin 9.4ng/ml (normal value: 30–400ng/ml). Chest radiograph revealed an infiltrate in the left upper lobe (LUL), disperse granulomas, and bilateral air trapping. Gastrointestinal endoscopy showed Candida esophagitis, erosive duodenitis with a negative urease test, and diverticula in the colon. Acid-fast bacilli were observed in 3 sputum samples, so treatment was initiated with isoniazid, rifampicin, pyrazinamide, and ethambutol, in addition to oral iron and fluconazole. After culture of 3 sputum samples in Löwenstein medium grew M. xenopi, the antimicrobial therapy was adjusted, and treatment began with clarithromycin, rifampicin, and ethambutol.

Chest computed tomography (CT) (Fig. 1) confirmed the existence of a solid lesion with a spiculated border and central cavitation in the LUL, measuring 40×35mm, with an 18mm-thick wall, contiguous with another paramediastinal lesion measuring 3cm, signs of emphysema and multiple calcified granulomas. No endoluminal lesions or changes in the mucosa were seen on bronchoscopy. PET-CT confirmed a hypermetabolic mass in the left lung apex, with the appearance of a malignant lung tumor. Transbronchial biopsy yielded a diagnosis of squamous cell carcinoma.

Fig. 1.

(A) Coronal CT with lung window: cavitating mass with thick irregular wall, 18mm in the left upper lobe extending toward the mediastinum. (B) Axial PET-CT: mass showing high uptake of fluorodeoxyglucose, with a standard uptake value of 28.38 units.

M. xenopi infections usually occur with nonspecific symptoms such as dyspnea, cough, and weight loss,6 and primarily affect males with COPD.7,8 Radiological changes are wide-ranging and usually persistent. Cavitating lesions in the upper lobes, masses, miliary nodules, and mediastinal or hilar adenopathies are common.9 Woodring and Fried10 found that the majority of cavities larger than 15mm in diameter were, as in our case, tumor disease. To our knowledge, 3 cases of M. xenopi infection associated with lung cancer have been published: adenocarcinoma,11 large cell carcinoma,5 and squamous cell carcinoma,12 none of which presented the 2 entities simultaneously, as observed in our case.

To diagnose these diseases, mycobacteria must be grown in 3 sputum cultures, and clinical and radiological evidence must be consistent.13 The best therapeutic combination and optimal treatment duration for M. xenopi lung infections remain to be determined. According to current criteria for NTM infection (ATS/IDSA 2007),8 a 12-month course of a combination of rifampicin, ethambutol, and clarithromycin (or moxifloxacin, due to its low inhibitory concentration against mycobacteria14) is recommended.

Although M. xenopi infection is exceptional, we believe that this case illustrates the importance of ruling out NTM infection in the case of co-existing symptoms or nonspecific signs such as weight loss or anemia in patients with COPD and lung cancer.

J. Banks,A.M. Hunter,I.A. Campbell,P.A. Jenkins,A.P. Smith
Pulmonary infection with Mycobacterium xenopi: review of treatment and response
Thorax, 39 (1984), pp. 376-382
V. Donnabella,J. Salazar-Schicchi,S. Bonk,B. Hanna,W.N. Rom
Increasing incidence of Mycobacterium xenopi at Bellevue hospital: an emerging pathogen or a product of improved laboratory methods?
Chest, 118 (2000), pp. 1365-1370
D.R. Prevots,T.K. Marras
Epidemiology of human pulmonary infection with nontuberculous mycobacteria. A review
Clin Chest Med, 36 (2015), pp. 13-34
P. Sexton,A.C. Harrison
Susceptibility to nontuberculous mycobacterial lung disease
Eur Respir J, 31 (2008), pp. 1322-1333
L. Lande,D.D. Peterson,R. Gogoi,G. Daum,K. Stampler,R. Kwait
Association between pulmonary Mycobacterium avium complex infection and lung cancer
J Thorac Oncol, 7 (2012), pp. 1345-1351
J. Mencarini,C. Cresci,M.T. Simonetti,C. Truppa,G. Camiciottoli,M.L. Frilli
Non-tuberculous mycobacteria: epidemiological pattern in a reference laboratory and risk factors associated with pulmonary disease
Epidemiol Infect, 145 (2017), pp. 515-522
C. Piersimoni,C. Scarparo
Pulmonary infections associated with non-tuberculous mycobacteria in immunocompetent patients
Lancet Infect Dis, 8 (2008), pp. 323-334
J.E. Stout,W.J. Koh,W.W. Yew
Update on pulmonary disease due to non-tuberculous mycobacteria
Int J Infect Dis, 45 (2016), pp. 123-134
M.C. Carrillo,D. Patsios,U. Wagnetz,F. Jamieson,T.K. Marras
Comparison of the spectrum of radiologic and clinical manifestations of pulmonary disease caused by Mycobacterium avium complex and Mycobacterium xenopi
Can Assoc Radiol J, 65 (2014), pp. 207-213
J.H. Woodring,A.M. Fried
Significance of wall thickness in solitary cavities of the lung: a follow-up study
Am J Roentgenol, 140 (1983), pp. 473-474
R. Souilamas,C. Danel,X. Chauffour,M. Riquet
Lung cancer occurring with Mycobacterium xenopi and Aspergillus
Eur J Cardiothorac Surg, 20 (2001), pp. 211-213
V.K. Doshi,S.R. Kulkarni,N.M. Kham,K.S. Kapitan
A Case of lung cancer originating from cavitary Mycobacterium xenopi infection
Respir Care, 60 (2015), pp. 56-58
D.E. Griffith,T. Aksamit,B.A. Brown-Eliott,A. Catanzaro,C. Daley,F. Gordin,ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America
An official ATS/IDSA statement: diagnosis, treatment, and prevéntion of nontuberculous mycobacterial diseases
Am J Respir Crit Care Med, 175 (2007), pp. 367-416
J.N. Dauendorffer,C. Laurain,M. Weber,M. Dailloux
In vitro sensivity of Mycobacterium xenopi to five antibiotics
Pathol Biol, 50 (2002), pp. 691-694

Please cite this article as: Martín Asenjo M, Martín Guerra JM, López Pedreira MR, Prieto de Paula JM. Mycobacterium xenopi y carcinoma pulmonar de células escamosas. Arch Bronconeumol. 2017;53:698–700.

Copyright © 2017. SEPAR
Archivos de Bronconeumología (English Edition)

Subscribe to our Newsletter

Article options
Cookies policy
To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.